Euglycemic Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Review of the Literature

This paper provides an overview of euglycemic diabetic ketoacidosis (euDKA) associated with the use sodium-glucose co-transporter 2 (SGLT2) inhibitors. euDKA is a rare but potentially life-threatening complication that can occur in patients taking SGLT2 inhibitors, and its clinical presentation differs from traditional ketoacidosis. discusses epidemiology, pathophysiology, manifestations, diagnosis, treatment euDKA. Prompt recognition appropriate are critical to prevent morbidity mortality. Healthcare providers should be aware potential risk inhibitors educate them on signs symptoms this serious complication. Further research needed better understand pathophysiology identify strategies for prevention treatment.